FranceFrance

Novel hepatitis C vaccine in sight

17.08.2011

Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope proteins Gag, E2 and E1. They have also demonstrated its efficacy in mice and macaques. Led by David Klatzmann from the Université Pierre et Marie Curie in Paris and Epixis’ CEO Charlotte Dalba, the researchers reported their findings in Science Translational Medicine (DOI: 10.1126/scitranslmed.3002330). The anti­bodies induced by the vaccine against HCV 1a cross-neutralised five other genotypes of HCV, offering hope that it would also beat back mutations as they occur. There is currently no available vaccine for hepatitis C, although several companies are developing therapeutic vaccines that are designed to help patients who are already infected. The VLP platform can be pseudotyped with a vast array of virus envelope glyco­proteins, which opens up a new approach to viral vaccine development. Dalba has said she hopes that initial human trials of the vaccine could start in 2012, provided funding was available. According to media reports, Epixis is in the process of being acquired by an undisclosed biotech company based in the US.

FranceFrance

28.03.2012

Minneapolis/Banzancourt – Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale. The French/US enterprise has now scaled up its...

FranceFrance

14.03.2012

Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version...

FranceFrance

13.03.2012

Paris/Barcelona – French pharma company Sanofi strengthens its ties with the Spanish research institution CGR (Center for Genomic Regulation) in Barcelona. CGR stated on 12 March that the two partners agreed upon three years of...

FranceFrance

06.03.2012

Lyon – The sale of 1.6 million shares brought in €25.3m for French Adocia SAS during its IPO on the Euronext Paris. The price of €15.88 values the diabetes specialist at €96.1m at the upper end of the bookbuilding range. Late...

FranceFrance

05.03.2012

Pointing to a new study on Syngenta’s GM maize Bt11, France’s Environment Ministry has asked the European Commission to suspend authorisation for the use of the MON810 maize sold by US agri­biotech giant Monsanto as well. The...

FranceFrance

27.02.2012

Cambridge - Genzyme will shut the doors at its Cambridge R&D site by the end of the year, with up to 60 employees expected to lose their jobs. The move is part of an ongoing global restructuring of R&D by Sanofi, who purchased...

FranceFrance

07.02.2012

Lille – Shares of the French diabetes specialist Genfit S.A. almost doubled when the company published results of its Phase II study with the PPAR alpha and delta modulator GFT505. The compound has met the co-primary and...

FranceFrance

06.02.2012

Shares of the French diabetes specialist almost doubled when the companypublished results of its Phase II study with the PPAR alpha and deltamodulator GFT505. The compound has met the co-primary and secondaryendpoints while...

FranceFrance

02.02.2012

Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an...

FranceFrance

12.01.2012

Berlin/Paris – Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain exclusive access to a modified strain of...

Displaying results 1 to 10 out of 268

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-france/article/novel-hepatitis-c-vaccine-in-sight.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%

FLOP

  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%

TOP

  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%

FLOP

  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%

TOP

  • SANTHERA82.40 CHF2139.1%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR141.3%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.6%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 19.10.2014


Current issue

All issues

Product of the week

Products